

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

### **華康生物醫學控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8622)**

## **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024**

Reference is made to the annual report of Huakang Biomedical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2024 (the “**2024 Annual Report**”). Unless otherwise defined, terms used herein shall have the same meaning as those defined in the 2024 Annual Report. This announcement provides supplemental information to the 2024 Annual Report and should be read in conjunction with the 2024 Annual Report.

### **SHARE OPTION SCHEME**

In addition to the information provided in the 2024 Annual Report, the Company wishes to provide to the shareholders and potential investors of the Company with the following additional information in relation to the Share Option Scheme pursuant to GEM Listing Rule 23.07(2).

- (i) The total number of shares which may be allotted and issued upon exercise of all options to be granted under the Share Option Scheme and any other shares option schemes of the Group must not in aggregate exceed 10% of the total number of shares in issue on the date which the Share Option Scheme is approved, which is 40,000,000 shares. As at 1 January 2024 and 31 December 2024, the number of options available for grant under the Share Option Scheme was 13,992,000 and 13,992,000 respectively.
- (ii) Within the scheme limit of the Share Option Scheme, no options are to be granted to service providers of the Group.

## FUNDRAISING

In addition to the information disclosed in the 2024 Annual Report, the Company wishes to provide the following supplemental information in relation to the First Placing 2024, the Second Placing 2024 and the Third Placing 2024 pursuant to GEM Listing Rule 18.32(8).

The net proceeds raised from the First Placing 2024, the Second Placing 2024 and the Third Placing 2024 were approximately HK\$1.98 million, HK\$3.17 million and HK\$2.96 million, respectively. As at 31 December 2024, the net proceeds from the First Placing 2024, the Second Placing 2024 and the Third Placing 2024 have been fully utilised.

The table below demonstrates the breakdown and description of the utilisation of the net proceeds from the First Placing 2024:

<b>Use of net proceeds from the First Placing 2024</b>	<i>HK\$' million</i> (approximately)	Approximate percentage of allocation
General working capital		
(i) salaries, rental and other corporate expenses	0.56	28.3%
(ii) professional fees	1.29	65.2%
(iii) other operating expenses	0.13	6.5%
<b>Total</b>	<b>1.98</b>	<b>100.0%</b>

The table below demonstrates the breakdown and description of the utilisation of the net proceeds from the Second Placing 2024:

<b>Use of net proceeds from the Second Placing 2024</b>	<i>HK\$' million</i> (approximately)	Approximate percentage of allocation
General working capital		
(i) salaries, rental and other corporate expenses	2.00	63.1%
(ii) professional fees	0.98	30.9%
(iii) other operating expenses	0.19	6.0%
<b>Total</b>	<b>3.17</b>	<b>100.0%</b>

The table below demonstrates the breakdown and description of the utilisation of the net proceeds from the Third Placing 2024:

<b>Use of net proceeds from the Third Placing 2024</b>	<i>HK\$' million</i> (approximately)	Approximate percentage of allocation
General working capital		
(i) salaries, rental and other corporate expenses	1.90	64.2%
(ii) professional fees	0.85	28.7%
(iii) other operating expenses	0.21	7.1%
<b>Total</b>	<u>2.96</u>	<u>100.0%</u>

The above supplemental information does not affect other information disclosed in the 2024 Annual Report. Save as disclosed above, the other information contained in the 2024 Annual Report remains unchanged.

On behalf of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Yujing**  
*Co-Chairman and Executive Director*

Hong Kong, 19 December 2025

*As at the date of this announcement, the Executive Directors are Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*